TITLE

Hypertension

PUB. DATE
August 1997
SOURCE
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS36
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Presents an abstract of the research manuscript `The ETA/B receptor antagonist bosentan reduces blood pressure in rats with reduced renal mass,' by R. Lariviere, S. Lacasse-M. et al from the Laval University. Endothelin-1 (ET).
ACCESSION #
9708236218

 

Related Articles

  • Hypertension.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS36 

    Presents an abstract of the research manuscript `Effect of chronic treatment with two different ETA-selective endothelin receptor antagonists on blood pressure and small artery structure of DOCA-salt hypertensive rats,' by E.L. Schiffrin, J.-S. Li and A. Turgeon from the University of Montreal.

  • Hypertension.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS41 

    Presents an abstract of the research manuscript `Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats,' by E.L. Schiffrin and A. Turgeon from the University of Montreal.

  • Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Wang, Andrew; Holcslaw, Terry; Bashore, Thomas M.; Freed, Martin I.; Miller, Diane; Rudnick, Michael R.; Szerlip, Harold; Thames, Marc D.; Davidson, Charles J.; Shusterman, Neil; Schwab, Steven J.; Wang, A; Holcslaw, T; Bashore, T M; Freed, M I; Miller, D; Rudnick, M R; Szerlip, H; Thames, M D; Davidson, C J // Kidney International;Apr2000, Vol. 57 Issue 4, p1675 

    Background: Endothelin is a potent vasoconstrictor that has been implicated in the pathogenesis of radiocontrast nephrotoxicity. Endothelin antagonists may reduce the renal hemodynamic abnormalities following radiocontrast administration. Methods: One hundred...

  • Hypertension.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS35 

    Presents an abstract of the research manuscript `Differential regulation of endothelin receptor expression by insulin and vanadate in rat aortic smooth muscle cells (ASMC),' by R.L. Hopfner, R.V. Hasnadka et al from the University of Saskatchewan.

  • Studies on Coronary Arteriopathy in Dogs Following Administration of CI-1020, an Endothelin A Receptor Antagonist. Albassam, Mudher A.; Metz, Alan L.; Potoczak, Ronald E.; Gallagher, Kim P.; Haleen, Stephen; Hallak, Hussein; McGuire, Edward J. // Toxicologic Pathology;May/Jun2001, Vol. 29 Issue 3, p277 

    A selective nonpeptide endothelin A (ETA) receptor antagonist, CI-1020, was administered to beagle dogs intravenously (iv) for 4 hours to 4 weeks. One animal/sex received CI-1020 at 1 mg/kg/hr intravenously for 4, 8, or 24 hours to investigate onset of arteriopathy. Control animals (1/sex)...

  • Endothelin antagonists in renal disease. Benigni, Ariela // Kidney International;Apr2000, Vol. 57 Issue 4, p1778 

    Examines the role of endothelin antagonists in renal disease. Presentation of a case study; Participation of endothelium in regulating vascular tone; Components of isopeptides.

  • ETRB antagonist stops melanoma cell growth. Guttman, Cheryl // Dermatology Times;Nov99, Vol. 20 Issue 11, p20 

    Focuses on results of preclinical investigations of endothelin receptor B antagonism. Innovative approach to the treatment of malignant melanoma; Benefits of adding BQ-788 to cultures of seven human melanoma cell lines; Utilization of nude mice injected with human melanoma cells.

  • Agent slows progression of refractory PCa. Newman, Laura // Urology Times;Jul2001, Vol. 29 Issue 7, p14 

    Reports that an endothelin-A receptor antagonist has been found to slow progression of refractory prostate cancer as of July 2001. Details of the study presented during the American Society of Clinical Oncology's year 2001 meeting held in San Francisco, California.

  • Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats. Lal, Mark A.; Korner, Anna; Matsuo, Yasutaka; Zelenin, Sergey; Cheng, Sam X.J.; Jaremko, Georg; DiBona, Gerald F.; Eklof, Ann-Christine; Aperia, Anita; Lal, M A; Körner, A; Matsuo, Y; Zelenin, S; Cheng, S X; Jaremko, G; DiBona, G F; Eklöf, A C; Aperia, A // Diabetes;Aug2000, Vol. 49 Issue 8, p1381 

    The development and progression of diabetic nephropathy is dependent on glucose homeostasis and many other contributing factors. In the present study, we examined the effect of nitecapone, an inhibitor of the dopamine-metabolizing enzyme catechol-O-methyl transferase (COMT) and a potent...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics